The Claim
In adults with heterozygous familial hypercholesterolemia (HeFH) who are already on statin therapy, the administration of 20 mg daily oral enlicitide for 24 weeks results in a median reduction of lipoprotein(a) levels by 24.7%, compared to a 1.6% reduction with placebo, yielding a statistically significant between-group difference of −27.5% (95% CI: −34.3% to −20.6%, p < 0.001), indicating an additional benefit on this genetically influenced cardiovascular risk factor.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For adults with a genetic cholesterol problem who are already taking cholesterol pills, adding a daily 20 mg pill called enlicitide for 6 months cuts a harmful type of blood fat (lipoprotein(a)) by about a quarter—way more than a dummy pill does.
See the scientific wording
In adults with heterozygous familial hypercholesterolemia (HeFH) on statin therapy, 20 mg daily oral enlicitide for 24 weeks reduces lipoprotein(a) levels by a median of 24.7% compared to a 1.6% reduction with placebo (between-group difference: −27.5%, 95% CI: −34.3% to −20.6%, p < 0.001), indicating an additional benefit on this genetically influenced cardiovascular risk factor.
What the research says
1 studyThe study tested the same pill, in the same kind of patients, for the same amount of time, and found it lowered a harmful blood fat called lipoprotein(a) just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.